Analyses of extrinsic and intrinsic factors which regulate the immune modulation in polytrauma
- Conditions
- S28T89T81T88T79T93T94T90I97R57
- Registration Number
- DRKS00017215
- Lead Sponsor
- Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Frankfurt, Goethe Universität
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
Age > 18 years
- Polytrauma with an ISS = 16
- regular termination of the shock room phase
- signed informed consent
Exclusion Criteria
- patients younger then 18
- burn injury
- death within 24 hours post trauma
- ISS < 16
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - cytokine-/chemokine profiles<br>- coagulation factors<br>- miRNA <br>- cell damage and function marker<br>- cells<br>- organ functions<br>- diagnoses <br>- duration of the stay at the intensive care unit and hospital<br>- organ failure, mortality<br><br>Time points for sampling:<br>- upon admission<br>- day 1<br>- day 2<br>- day 3<br>- day 5<br>- day 7<br>- day 10
- Secondary Outcome Measures
Name Time Method - differential blood analysis (clinical routine)<br>- infections (pneumonia, wound infections, etc.) (clinical routine)<br>- SIRS, severe SIRS (clinical routine)<br>- sepsis, severe sepsis, septic shock<br>- shock severity (katecholamin concentration)<br>- organ dysfunctions (SOFA score)<br>- injury severity (ISS)<br>- disease severity (APACHE II, SAPS II, SAPS 3)<br>- regenerative disturbances (clinical routine)<br>- complications (clinical routine)<br>- mortality <br>- clinical data from the German Trauma Registry<br>- transfusion (clinical routine, BGAs)<br>- perioperative complications e.g. lung embolism, myocardial infarction<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways (e.g., TLR signaling, cytokine profiles) mediate immune suppression in polytrauma patients with thoracic injuries and traumatic amputations?
How do extrinsic (e.g., injury severity, environmental stressors) and intrinsic (e.g., genetic predispositions) factors differentially impact immune modulation in polytrauma patients with multiple complications?
Which biomarkers (e.g., HLA alleles, DAMPs) predict immune response variability in polytrauma patients with conditions like DIC and heart failure?
What are the key immune-related complications (e.g., sepsis, ARDS) observed in polytrauma patients with thoracic trauma and how are they managed?
What are the potential targets for immunomodulatory therapies (e.g., anti-inflammatory agents, cytokine inhibitors) in polytrauma-induced systemic immune dysfunction?